Cargando…

Prevalence and significance of incidental findings on 68 Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT: a systematic review of the literature

AIM: We aimed to evaluate the prevalence of incidental (68) Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET/CT (SSTR PET/CT) findings, their clinical significance in the need for follow-up, and their risk of malignancy. MATERIALS AND METHODS: Studies reporting incidental SSTR PET/CT f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bentestuen, Morten, Gossili, Farid, Almasi, Charlotte Elberling, Zacho, Helle Damgaard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441055/ https://www.ncbi.nlm.nih.gov/pubmed/36057635 http://dx.doi.org/10.1186/s40644-022-00484-0

Ejemplares similares

A Case of Penile Metastasis from Prostate Cancer, Identified by (68)Ga-PSMA PET/CT, Mimicking Peyronie’s Disease: A Diagnostic Challenge
por: Gossili, Farid, et al.
Publicado: (2023)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Intense PSMA Uptake in a Vertebral Hemangioma Mimicking a Solitary Bone Metastasis in the Primary Staging of Prostate Cancer via (68)Ga-PSMA PET/CT
por: Gossili, Farid, et al.
Publicado: (2023)

Prevalence of Brain Incidental Lesions Detected by (68)Ga-DOTA Peptides PET/CT
por: Albano, Domenico, et al.
Publicado: (2022)

Not All Glittering Bone Lesions Are Gold: A Case of Sclerotic Bone Lesions with Elevated (68) Ga PSMA and (99m) Tc HDP Uptake with No Signs of Malignancy
por: Bentestuen, Morten, et al.
Publicado: (2022)

Standardized image quality for (68)Ga-DOTA-TATE PET/CT
por: Cox, Christina P. W., et al.
Publicado: (2020)

PET-CT imaging of pulmonary inflammation using [(68)Ga]Ga-DOTA-TATE
por: Puuvuori, Emmi, et al.
Publicado: (2022)

Diagnostic challenges in a patient with an occult insulinoma:(68 )Ga‐DOTA‐exendin‐4 PET/CT and (68)Ga‐DOTATATE PET/CT
por: Bongetti, Elisa, et al.
Publicado: (2018)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

The role of (68)Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome
por: Ceccato, Filippo, et al.
Publicado: (2020)

The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
por: Novruzov, Fuad, et al.
Publicado: (2021)

Head-to-Head Comparison of (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study
por: Hou, Guozhu, et al.
Publicado: (2022)

Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy
por: Kiviniemi, Aida, et al.
Publicado: (2015)

Application of (68)Ga-DOTA-TATE PET/CT in metastatic neuroendocrine tumor of gastrointestinal origin
por: Papadakis, Georgios Z., et al.
Publicado: (2017)

Preoperative (68)Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions
por: Norlén, Olov, et al.
Publicado: (2017)

Changes in biodistribution on (68)Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
por: Cherk, Martin H., et al.
Publicado: (2018)

Pancreatic serous cystoadenoma (CSA) showing increased tracer uptake at 68-GaDOTA-peptide Positron Emission Tomography (68Ga-DOTA-peptide PET-CT): a case report
por: Nappo, Gennaro, et al.
Publicado: (2020)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

Same-day comparative protocol PET/CT-PET/MRI [(68) Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine
por: Prado-Wohlwend, Stefan, et al.
Publicado: (2023)

Assessment of regional pulmonary blood flow using (68)Ga-DOTA PET
por: Velasco, Carlos, et al.
Publicado: (2017)

Giant Hepatic Artery Aneurysm
por: Gossili, Farid, et al.
Publicado: (2019)

(68)Ga-DOTA-Siglec-9 PET/CT imaging of peri-implant tissue responses and staphylococcal infections
por: Ahtinen, Helena, et al.
Publicado: (2014)

Impact of segmentation and discretization on radiomic features in (68)Ga-DOTA-TOC PET/CT images of neuroendocrine tumor
por: Liberini, Virginia, et al.
Publicado: (2021)

(68)Ga-DOTA-DiPSMA PET/CT Imaging: Biodistribution, Dosimetry, and Preliminary Application in Prostate Cancer
por: Zhang, Jiaying, et al.
Publicado: (2022)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Small cell lung cancer mimicking lymphoma in CT and (68)Ga-DOTA-NOC PET/CT: A case report
por: Lu, Liyan, et al.
Publicado: (2018)

Postoperative [(68)Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1
por: Teske, Nico, et al.
Publicado: (2023)

SAT-575 Radiolabeled Somatostatin Receptor Analog (86)Y-EB-TATE is Characterized by Superior Tumor Uptake Compared to (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 in Thyroid Cancer Mice Models
por: Thakur, Shilpa, et al.
Publicado: (2019)

Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of (68)Ga DOTA-TATE PET/CT, (111)In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors
por: Froelich, Matthias Frank, et al.
Publicado: (2021)

The Search for an Alternative to [(68)Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of (18)F-labeled Somatostatin Analog Development
por: Waldmann, Christopher M., et al.
Publicado: (2019)

Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors
por: Opalińska, Marta, et al.
Publicado: (2022)

Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma
por: Gu, Bingxin, et al.
Publicado: (2022)

Diagnostic performance and impact on patient management of [(68)Ga]Ga-DOTA-TOC PET/CT in colorectal neuroendocrine tumors derived from hindgut
por: Delabie, Pierre, et al.
Publicado: (2022)

Preparation and Biological Study of (68)Ga-DOTA-alendronate
por: Fakhari, Ashraf, et al.
Publicado: (2016)

Ga-68 DOTA-NOC PET/CT for the Detection of Residual/Recurrence in a Rare Case of Sacral Spinal Canal Paraganglioma
por: Jain, Tarun Kumar, et al.
Publicado: (2016)

Role of Combined [(68)Ga]Ga-DOTA-SST Analogues and [(18)F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
por: Carideo, Luciano, et al.
Publicado: (2019)

Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [(68)Ga]Ga-DOTA-E-[c(RGDfK)](2) PET/CT
por: Lobeek, D., et al.
Publicado: (2020)

Initial Clinical Experience with (68)Ga-DOTA-NOC Prepared Using (68)Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based (68)Ge/(68)Ga Generator and Freeze-dried DOTA-NOC Kits
por: Chandra, Piyush, et al.
Publicado: (2017)

Monte Carlo investigation of PET [(68)Ga]Ga-DOTA-TOC activity-administration protocols for consistent image quality
por: Kalaitzidis, Philip, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ck0ai4sr0l8mgnrj8gb7i0ptde